Scott A. King Expects Strong Start to 2026 with Q1 Revenue of $176.6M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Reports Q1 revenue $176.6M, consensus $170.61M. Scott A. King, CEO, commented, "We delivered a strong start to 2026, with solid sales growth, meaningful margin expansion, and record earnings. Our results reflect the impact of pricing actions, a favorable product mix, improved leverage across labor, overhead, and SG&A, and efficient execution across our operations. Demand remained broad-based across most of our end markets with incoming order volumes supporting sales growth and increasing our backlog, which we believe positions us well for the remainder of the year. We also generated strong operating cash flow and reduced debt during the quarter. As we move forward, we remain focused on disciplined execution, investing appropriately in the business, and delivering long-term profitable growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRC
About GRC
The Gorman-Rupp Company designs, manufactures, and sells pumps and pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire suppression, heating, ventilating and air conditioning (HVAC), military and other liquid-handling applications. The Company’s product line consists of pump models ranging in size from 1/4 to nearly 15 feet and ranging in rated capacity from less than one gallon per minute to nearly one million gallons per minute. The types of pumps which the Company produces include self-priming centrifugal, standard centrifugal, magnetic drive centrifugal, axial and mixed-flow, vertical turbine line shaft, submersible, high-pressure booster, rotary gear, rotary vein, diaphragm, bellows and oscillating. Its pumps have driven that range from fractional horsepower electric motors up to larger electric motors or internal combustion engines capable of producing several thousand horsepower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie: A Top Pick in Uncertain Markets
- Stable Dividend Record: AbbVie has increased its dividend for 53 consecutive years since its spin-off in 2013, demonstrating business stability that attracts investors seeking safe investments in uncertain market conditions.
- Strong Sales Growth: AbbVie's two successors to Humira, Rinvoq and Skyrizi, are already generating higher sales than Humira at its peak, indicating the company's successful navigation of patent cliffs and laying a foundation for future growth.
- Relatively Undervalued Valuation: AbbVie’s forward P/E ratio of 14.7 is significantly lower than the healthcare sector's 16.8, highlighting its attractiveness among peers, especially as many other Dividend Kings are trading at higher valuations.
- Diverse Growth Drivers: AbbVie has enhanced its product portfolio through acquisitions of the antipsychotic drug Vraylar and migraine therapies Qulipta and Ubrelvy, increasing its growth potential and catering to various types of investors' needs.
See More
AbbVie: An Ideal Pick During Uncertain Times
- Stable Business Model: AbbVie has increased its dividend for 53 consecutive years since its founding in 1888, demonstrating strong business stability that attracts shareholders seeking safe investments, especially in uncertain market conditions.
- Strong Growth Prospects: AbbVie's revenue jumped 12.4% year-over-year in Q1 2026, while its competitor Hormel Foods only saw a 2% increase, showcasing its competitive edge and future growth potential in the pharmaceutical industry.
- Attractive Dividend Yield: With a dividend yield exceeding 3.2%, AbbVie significantly outperforms many other Dividend Kings, such as Walmart's 0.74%, making it more appealing to income-focused investors.
- Valuation Advantage: AbbVie's forward price-to-earnings ratio of 14.7 is below the healthcare sector's 16.8, indicating attractive investment value in the current market, particularly amid increasing economic uncertainty.
See More
Aurora Investment Counsel Liquidates Gorman-Rupp Stake
- Liquidation Transaction: Aurora Investment Counsel sold its entire 58,061-share stake in Gorman-Rupp during Q1 2026 for an estimated $3.43 million, reflecting a $2.77 million decrease in the position's value from the previous quarter, indicating a decline in market confidence towards GRC.
- Asset Allocation Shift: The liquidation reduced Gorman-Rupp's stake from 1.5% to 0%, with Aurora's top holdings now including ZTO, DELL, and INTU, suggesting a strategic reallocation that may impact future investment strategies.
- Stock Performance: As of May 5, 2026, Gorman-Rupp shares were priced at $77.43, up 115.7% year-over-year, outperforming the S&P 500 by 87.3 percentage points, highlighting the company's strong performance in the industrial machinery sector but raising valuation concerns.
- Valuation Risks: Gorman-Rupp's price-to-earnings ratio is nearly 35x, exceeding the market average of 32x and its own 10-year average of 31x, indicating that while benefiting from AI infrastructure spending, the high valuation may limit future investment appeal.
See More
Aurora Investment Counsel Liquidates Gorman-Rupp Stake
- Complete Liquidation: Aurora Investment Counsel sold its entire stake of 58,061 shares in Gorman-Rupp during Q1 2026, with an estimated transaction value of $3.43 million, indicating a significant reduction in confidence towards the stock as it no longer represents any of their assets.
- Decline in Asset Value: The sale resulted in a $2.77 million decrease in the value of Aurora's Gorman-Rupp position from the previous quarter, reflecting both market price fluctuations and a strategic shift in Aurora's investment approach.
- Strong Market Performance: Despite Aurora's exit, Gorman-Rupp shares have surged 115.7% over the past year, outperforming the S&P 500 by 87.3 percentage points, highlighting the company's robust growth potential in the industrial machinery sector.
- Valuation Risks Emerge: Gorman-Rupp's current price-to-earnings ratio stands at nearly 35x, exceeding the market average of 32x and its own 10-year average of 31x, prompting investors to carefully consider the risks associated with its high valuation.
See More
The Gorman-Rupp Company Declares Quarterly Cash Dividend
- Quarterly Cash Dividend: The Board of Directors of The Gorman-Rupp Company has declared a cash dividend of $0.19 per share, payable on June 10, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Consecutive Dividend Record: This dividend marks the 305th consecutive quarterly dividend paid by The Gorman-Rupp Company, underscoring its long-term commitment to stable cash flow and shareholder value creation.
- Company Background: Founded in 1933, The Gorman-Rupp Company is a leading designer, manufacturer, and international marketer of pumps and pump systems used across diverse sectors including water, industrial, and agricultural applications, showcasing its diversified market presence.
- Forward-Looking Statements: The company cautions that future performance is subject to various economic, political, and technological uncertainties, indicating a prudent approach to navigating market challenges and potential risks to its operations.
See More
Gorman-Rupp Q1 Earnings Exceed Expectations
- Strong Performance: Gorman-Rupp reported a Q1 GAAP EPS of $0.68, beating estimates by $0.15, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
- Revenue Growth: The company achieved revenues of $176.6 million, a 7.7% year-over-year increase that surpassed expectations by $5.99 million, primarily driven by demand growth across various markets and price increases, showcasing robust performance in diversified sectors.
- Market Performance: Sales increased by $6.3 million in the construction market, $4.4 million in agriculture, $3.5 million in industrial, and $2.9 million in municipal sectors, highlighting strong demand driven by infrastructure investments and domestic spending, further solidifying the company's market position.
- Order and Debt Management: Incoming orders reached $187.5 million, up 5.5% year-over-year, with backlog increasing to $247.9 million, while the company reduced total debt by $15 million in the first three months, demonstrating strong financial health and effective debt management.
See More
AbbVie: A Top Pick in Uncertain Markets
- Stable Dividend Record: AbbVie has increased its dividend for 53 consecutive years since its spin-off in 2013, demonstrating business stability that attracts investors seeking safe investments in uncertain market conditions.
- Strong Sales Growth: AbbVie's two successors to Humira, Rinvoq and Skyrizi, are already generating higher sales than Humira at its peak, indicating the company's successful navigation of patent cliffs and laying a foundation for future growth.
- Relatively Undervalued Valuation: AbbVie’s forward P/E ratio of 14.7 is significantly lower than the healthcare sector's 16.8, highlighting its attractiveness among peers, especially as many other Dividend Kings are trading at higher valuations.
- Diverse Growth Drivers: AbbVie has enhanced its product portfolio through acquisitions of the antipsychotic drug Vraylar and migraine therapies Qulipta and Ubrelvy, increasing its growth potential and catering to various types of investors' needs.
See More
AbbVie: An Ideal Pick During Uncertain Times
- Stable Business Model: AbbVie has increased its dividend for 53 consecutive years since its founding in 1888, demonstrating strong business stability that attracts shareholders seeking safe investments, especially in uncertain market conditions.
- Strong Growth Prospects: AbbVie's revenue jumped 12.4% year-over-year in Q1 2026, while its competitor Hormel Foods only saw a 2% increase, showcasing its competitive edge and future growth potential in the pharmaceutical industry.
- Attractive Dividend Yield: With a dividend yield exceeding 3.2%, AbbVie significantly outperforms many other Dividend Kings, such as Walmart's 0.74%, making it more appealing to income-focused investors.
- Valuation Advantage: AbbVie's forward price-to-earnings ratio of 14.7 is below the healthcare sector's 16.8, indicating attractive investment value in the current market, particularly amid increasing economic uncertainty.
See More
Aurora Investment Counsel Liquidates Gorman-Rupp Stake
- Liquidation Transaction: Aurora Investment Counsel sold its entire 58,061-share stake in Gorman-Rupp during Q1 2026 for an estimated $3.43 million, reflecting a $2.77 million decrease in the position's value from the previous quarter, indicating a decline in market confidence towards GRC.
- Asset Allocation Shift: The liquidation reduced Gorman-Rupp's stake from 1.5% to 0%, with Aurora's top holdings now including ZTO, DELL, and INTU, suggesting a strategic reallocation that may impact future investment strategies.
- Stock Performance: As of May 5, 2026, Gorman-Rupp shares were priced at $77.43, up 115.7% year-over-year, outperforming the S&P 500 by 87.3 percentage points, highlighting the company's strong performance in the industrial machinery sector but raising valuation concerns.
- Valuation Risks: Gorman-Rupp's price-to-earnings ratio is nearly 35x, exceeding the market average of 32x and its own 10-year average of 31x, indicating that while benefiting from AI infrastructure spending, the high valuation may limit future investment appeal.
See More
Aurora Investment Counsel Liquidates Gorman-Rupp Stake
- Complete Liquidation: Aurora Investment Counsel sold its entire stake of 58,061 shares in Gorman-Rupp during Q1 2026, with an estimated transaction value of $3.43 million, indicating a significant reduction in confidence towards the stock as it no longer represents any of their assets.
- Decline in Asset Value: The sale resulted in a $2.77 million decrease in the value of Aurora's Gorman-Rupp position from the previous quarter, reflecting both market price fluctuations and a strategic shift in Aurora's investment approach.
- Strong Market Performance: Despite Aurora's exit, Gorman-Rupp shares have surged 115.7% over the past year, outperforming the S&P 500 by 87.3 percentage points, highlighting the company's robust growth potential in the industrial machinery sector.
- Valuation Risks Emerge: Gorman-Rupp's current price-to-earnings ratio stands at nearly 35x, exceeding the market average of 32x and its own 10-year average of 31x, prompting investors to carefully consider the risks associated with its high valuation.
See More
The Gorman-Rupp Company Declares Quarterly Cash Dividend
- Quarterly Cash Dividend: The Board of Directors of The Gorman-Rupp Company has declared a cash dividend of $0.19 per share, payable on June 10, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Consecutive Dividend Record: This dividend marks the 305th consecutive quarterly dividend paid by The Gorman-Rupp Company, underscoring its long-term commitment to stable cash flow and shareholder value creation.
- Company Background: Founded in 1933, The Gorman-Rupp Company is a leading designer, manufacturer, and international marketer of pumps and pump systems used across diverse sectors including water, industrial, and agricultural applications, showcasing its diversified market presence.
- Forward-Looking Statements: The company cautions that future performance is subject to various economic, political, and technological uncertainties, indicating a prudent approach to navigating market challenges and potential risks to its operations.
See More
Gorman-Rupp Q1 Earnings Exceed Expectations
- Strong Performance: Gorman-Rupp reported a Q1 GAAP EPS of $0.68, beating estimates by $0.15, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
- Revenue Growth: The company achieved revenues of $176.6 million, a 7.7% year-over-year increase that surpassed expectations by $5.99 million, primarily driven by demand growth across various markets and price increases, showcasing robust performance in diversified sectors.
- Market Performance: Sales increased by $6.3 million in the construction market, $4.4 million in agriculture, $3.5 million in industrial, and $2.9 million in municipal sectors, highlighting strong demand driven by infrastructure investments and domestic spending, further solidifying the company's market position.
- Order and Debt Management: Incoming orders reached $187.5 million, up 5.5% year-over-year, with backlog increasing to $247.9 million, while the company reduced total debt by $15 million in the first three months, demonstrating strong financial health and effective debt management.
See More
